Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesA phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors
Journal of Neuro-Oncology, 09/28/09
Rosenfeld A et al. – High risk/recurrent CNS tumors have a poor prognosis. We studied tandem high dose chemotherapy (HDC) with hematopoietic progenitor stem cell rescues (HPCR) as potentially curative therapy. Toxicity was significant with six treatment related deaths including four with veno–occlusive disease. This regimen of sequential HDC/HPCR in high risk/recurrent CNS tumor patients is not feasible due to toxicity.
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Cancer Management and Research, 11/05/09
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
Journal of Clinical Oncology, 11/12/09
Clinical Analysis of Novalis Stereotactic Radiosurgery for Brain Metastases
Journal of Korean Neurosurgical Society, 10/30/09
Sponsor
Article Search
Sponsor